Due to the increase in cases of COVID-19 and the emergence of the Omicron variant, there may be logistical or supply constraints that make it impossible to offer the available therapy to all eligible patients, making patient triage necessary. This SO has been revised to provide patient prioritization criteria.

**Purpose:** To meet the goal of administering FDA-Emergency Use Authorization casirivimab/imdevimab (REGEN-COV) to treat mild to moderate coronavirus disease, or for post-exposure prophylaxis (PEP) of COVID-19, in patients who are high risk for progression to severe COVID-19 and who meet the criteria set-forth by the Emergency Use Authorization Food and Drug Administration.

**Policy:** This standing order authorizes any North Carolina healthcare provider, in accordance with the conditions of their licensure and/or scope of practice to include subcutaneous injections, or pursuant to orders issued under North Carolina Executive Order 245, or as a covered person under the federal PREP Act functioning as monoclonal antibody providers to administer casirivimab/imdevimab (REGEN-COV) authorized by the FDA through an Emergency Use Authorization (EUA) and per conditions of this order.

<table>
<thead>
<tr>
<th>Condition or Situation</th>
<th>Casirivimab/Imdevimab (REGEN-COV) Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Attention Providers:</strong> Casirivimab/imdevimab (REGEN-COV) is not an effective treatment against the Omicron variant of COVID-19. REGEN-COV can only be administered in settings that have capability to rule out the omicron variant (e.g., by S gene Target Failure in the ThermoFisher TaqPath assay) as cause of patient illness and can administer treatment within 48 hours of results.</td>
<td></td>
</tr>
<tr>
<td>*Patients aged 12 years and older, weighing at least 40 kg (88.2 lb.), who present requesting and consent to receiving monoclonal antibodies (casirivimab/imdevimab or REGEN-COV) for treatment of mild to moderate COVID-19 who self-attest to being at high risk for severe COVID-19 disease. Patients should have legal and decisional capacity to consent to treatment with monoclonal antibodies (casirivimab/imdevimab or REGEN-COV), in accordance with NC GS § 91-21.13 and NC GS § 90-21.5.</td>
<td></td>
</tr>
<tr>
<td>*Casirivimab/imdevimab (REGEN-COV) can only be administered in settings in which healthcare providers have immediate access to medications to treat a severe infusion/injection or hypersensitivity reaction (such as anaphylaxis), and the ability to activate EMS, as necessary and according to local protocol.</td>
<td></td>
</tr>
</tbody>
</table>

**Assessment Criteria**

**Subjective**

1. Patient self-attests to positive results of SARS-CoV-2 viral testing AND
2. The patient presents within 10 days of symptom onset of COVID-19
3. In addition to the above criteria, the patient self-attests to ONE of the following:
   - Vaccinated individuals who are moderately to severely immunocompromised, who may not mount an adequate immune response to COVID-19 vaccination or SARS-CoV-2 infection due to their underlying conditions. (For examples...
## Objective

1. The patient is at least 12 years of age or older.
2. The patient weighs at least 40 kg, or 88.2 lb.

### Plan of Care

#### Actions

1. Review agency protocol for assessment and management of anaphylaxis before initiating treatment. Appropriate medical treatment and clinical staff able to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration reaction according to agency protocol.

2. Prior to patients receiving casirivimab/imdevimab (REGEN-COV), provide and review the Fact Sheet for Patients, Parents and Caregivers EUA of REGEN-COV for COVID-19.

3. Before administering casirivimab/imdevimab (REGEN-COV) or participating in any patient care activities, don appropriate personal protective equipment (PPE) per CDC guidelines to protect against the transmission of COVID-19.

#### Precautions: Patient Monitoring

The patient should be clinically monitored during and after administration of casirivimab/imdevimab (REGEN-COV). After administration is complete, the patient should be monitored for a minimum of 1 hour. During this time, the nurse, EMS personnel, or other individuals who are trained and supervised by clinical staff shall observe for signs and symptoms of a hypersensitivity reaction (anaphylaxis) or infusion/injection related reaction. These may include:

1. Fever
2. Difficulty breathing
3. Reduced oxygen saturation
4. Chills
5. Nausea
6. Arrhythmia (such as atrial fibrillation, tachycardia, or bradycardia)
7. Chest pain or discomfort
8. Weakness
9. Altered mental status
10. Headache
11. Bronchospasm
12. Hypotension
13. Hypertension
14. Angioedema

of immunocompromised conditions, see this link: Moderately or Severely Immunocompromised People) or
- Unvaccinated individuals aged 65 or older (with or without an underlying condition) or
- Unvaccinated individuals under age 65 with underlying medical condition that puts them at greatest risk for severe disease. (For examples of medical conditions that increase risk of severe disease, see this link: People with Certain Medical Conditions).
### Treatment

**Subcutaneous Route**

1. Prepare 600 mg casirivimab and 600 mg imdevimab according to manufacturer instructions using aseptic technique into FOUR separate syringes. Casirivimab and imdevimab can be supplied as either a co-formulated package (REGEN-COV), or individually packaged. Refer to the Fact Sheet for Health Care Providers EUA of REGEN-COV for the most updated guidance on medication preparation for casirivimab/imdevimab.

### Preparation of Casirivimab/Imdevimab for Subcutaneous Injection

<table>
<thead>
<tr>
<th>Prepare 600 mg of Casirivimab and 600 mg of Imdevimab</th>
<th>Prepare 4 Syringes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Co-Formulated Vial</td>
<td>Withdraw 2.5 mL solution per syringe into FOUR separate syringes</td>
</tr>
<tr>
<td>Individual Vials</td>
<td><strong>Casirivimab</strong>: Withdraw 2.5 mL solution per syringe into TWO separate syringes</td>
</tr>
<tr>
<td></td>
<td><strong>Imdevimab</strong>: Withdraw 2.5 mL solution per syringe into TWO separate syringes</td>
</tr>
</tbody>
</table>

2. Replace the 21-gauge transfer needle used for medication preparation with a 25-gauge or 27-gauge needle for subcutaneous injection. The recommended needle size for subcutaneous injections is 5/8”.

3. Administer the subcutaneous injections consecutively, each at a different injection site, into the thigh, back of the upper arm, and different quadrants of the abdomen, except for 2 inches (5 cm) around the navel. The waistline should be avoided.
   a. When choosing injection sites, avoid skin that is tender, damaged, bruised, or scarred.
   b. Follow local protocol for administering a subcutaneous injection.
**Follow-up**

1. Provide the patient with [COVID-19 Antibody Therapy Discharge Instructions](#) and review it with them.
2. Patients treated with casirivimab/imdevimab (REGEN-COV) should continue to use infection precautions and isolate or quarantine according to CDC Criteria for Quarantine and Isolation.
3. Administrators of casirivimab/imdevimab (REGEN-COV) should report all medication errors and serious adverse events within 7 days from the onset of the event. This can be found here: [http://www.fda.gov/medwatch/report.htm](http://www.fda.gov/medwatch/report.htm). Please note, all fields should be completed with as much detailed information as possible.

**Contraindications for Use of this Order**

Do not administer casirivimab/imdevimab (REGEN-COV) monoclonal antibody treatment to patients that:

1. Have previous severe hypersensitivity reaction, such as anaphylaxis, to casirivimab/imdevimab (REGEN-COV) or to any ingredient of casirivimab/imdevimab (REGEN-COV).
4. Require an increase in baseline oxygen flow rate due to COVID-19 for patients on chronic oxygen therapy due to underlying non-COVID-19 related morbidity.

**Criteria or Circumstances for Notifying the Physician or Advanced Practice Provider (APP)**

Notify the physician/APP if:

1. The patient desires treatment or post-exposure prophylaxis with casirivimab/imdevimab (REGEN-COV) but is uncertain if they meet the assessment criteria for use.
2. The patient exhibits signs of a hypersensitivity reaction (anaphylaxis) or an infusion/injection-related reaction. In this instance, stop treatment; initiate emergency medical protocols and notify the physician/APP providing clinical supervision of the treatment facility/agency/service.
3. Notify the physician/APP from the organization providing clinical supervision of the treatment facility/agency/service at any time there are questions or problems with carrying out this standing order.

---

*Note: use of REGEN-COV for post-exposure prophylaxis to COVID-19 is not directed under this standing order. The repeat dosing instructions for ongoing exposure to COVID-19 have therefore been omitted.*

Elizabeth Cuervo Tilson, MD, MPH
NPI: 1760540421

SWSO REGEN-COV 01/5/2022
This order is effective immediately upon signing and may be revised or revoked by the State Health Director according to his/her discretion. Legal Authority: Executive Order 245